Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Cutlip, S. Windecker, R. Mehran, A. Boam, D. Cohen, G. Es, P. Steg, M. Morel, L. Mauri, P. Vranckx, E. Mcfadden, A. Lansky, M. Hamon, M. Krucoff, P. Serruys (2007)
Clinical End Points in Coronary Stent Trials: A Case for Standardized DefinitionsCirculation, 115
G. Montalescot, S. Wiviott, E. Braunwald, S. Murphy, C. Gibson, C. Mccabe, E. Antman (2009)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 373
R. Mehran, Alexandra Lansky, B. Witzenbichler, G. Guagliumi, J. Peruga, B. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. Gersh, S. Pocock, S. Wong, E. Nikolsky, L. Gambone, Lynn Vandertie, H. Parise, G. Dangas, G. Stone (2009)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trialThe Lancet, 374
K. Fox, S. Goodman, W. Klein, D. Brieger, P. Steg, O. Dabbous, Á. Avezum (2002)
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).European heart journal, 23 15
S. Yusuf, F. Zhao, S. Mehta, S. Chrolavicius, G. Tognoni, K. Fox, Clopidogrel Investigators (2001)
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.The New England journal of medicine, 345 7
J. Mega, E. Braunwald, S. Wiviott, J. Bassand, Deepak Bhatt, C. Bode, P. Burton, Marc Cohen, N. Cook-Bruns, K. Fox, S. Goto, S. Murphy, A. Plotnikov, D. Schneider, Xiang Sun, F. Verheugt, C. Gibson (2012)
Rivaroxaban in patients with a recent acute coronary syndrome.The New England journal of medicine, 366 1
P. Steg, S. Mehta, J. Jukema, G. Lip, C. Gibson, F. Kovář, P. Kala, A. García-Hernandez, R. Renfurm, C. Granger (2011)
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeEuropean Heart Journal, 32
L. Wallentin, R. Wilcox, W. Weaver, H. Emanuelsson, Andrew Goodvin, P. Nyström, A. Bylock (2003)
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialThe Lancet, 362
S. Hohnloser, J. Oldgren, Sean Yang, L. Wallentin, M. Ezekowitz, P. Reilly, J. Eikelboom, M. Brueckmann, S. Yusuf, S. Connolly (2012)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 125
S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, J. Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin, C. Joyner, K. Fox (2006)
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.JAMA, 295 13
M. Patel, K. Mahaffey, Jyotsna Garg, Guohua Pan, D. Singer, W. Hacke, G. Breithardt, J. Halperin, G. Hankey, J. Piccini, R. Becker, C. Nessel, J. Paolini, S. Berkowitz, K. Fox, R. Califf (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.The New England journal of medicine, 365 10
SJ Connolly, MD Ezekowitz, S Yusuf (2009)
Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363(19):1877]., 361
Christopher Granger, J. Alexander, John McMurray, R. Lopes, E. Hylek, M. Hanna, H. Al-Khalidi, J. Ansell, D. Atar, Á. Avezum, M. Bahit, Rafael Diaz, J. Easton, J. Ezekowitz, Greg Flaker, David Garcia, M. Geraldes, B. Gersh, S. Golitsyn, S. Goto, A. Hermosillo, S. Hohnloser, John Horowitz, Puneet Mohan, P. Janský, Basil Lewis, J. López-Sendón, P. Pais, A. Parkhomenko, F. Verheugt, Jun Zhu, L. Wallentin (2011)
Apixaban versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 365 11
J. Schmitt, G. Duray, B. Gersh, S. Hohnloser (2009)
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications.European heart journal, 30 9
R. Wright, Jeffrey Anderson, C. Adams, C. Bridges, D. Casey, S. Ettinger, F. Fesmire, T. Ganiats, H. Jneid, A. Lincoff, E. Peterson, G. Philippides, P. Théroux, N. Wenger, J. Zidar, E. Antman, R. Califf, W. Chavey, J. Hochman, T. Levin (2011)
2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed inJournal of the American College of Cardiology, 57 19
R. Wright, Jeffrey Anderson, C. Adams, C. Bridges, D. Casey, S. Ettinger, F. Fesmire, T. Ganiats, H. Jneid, A. Lincoff, E. Peterson, G. Philippides, P. Théroux, N. Wenger, J. Zidar, E. Antman, R. Califf, W. Chavey, J. Hochman, T. Levin, N. Wenger (2011)
2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in cJournal of the American College of Cardiology, 57 19
S. Connolly, M. Ezekowitz, S. Yusuf, P. Reilly, L. Wallentin (2010)
Newly identified events in the RE-LY trial.The New England journal of medicine, 363 19
SD Wiviott, E Braunwald, DJ Angiolillo (2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38., 118
D. Holmes, D. Kereiakes, N. Kleiman, D. Moliterno, G. Patti, C. Grines (2009)
Combining antiplatelet and anticoagulant therapies.Journal of the American College of Cardiology, 54 2
DF Stroup, JA Berlin, SC Morton (2000)
Meta-analysis of Observational Studies in Epidemiology: a proposal for reporting., 283
J. Alexander, R. Lopes, S. James, R. Kilaru, Yaohua He, Puneet Mohan, Deepak Bhatt, S. Goodman, F. Verheugt, M. Flather, K. Huber, Danny Liaw, S. Husted, J. López-Sendón, R. Caterina, P. Janský, H. Darius, D. Vinereanu, J. Cornel, F. Cools, D. Atar, J. Leiva-Pons, M. Keltai, H. Ogawa, P. Pais, A. Parkhomenko, W. Rużyłło, R. Diaz, H. White, M. Ruda, M. Geraldes, J. Lawrence, R. Harrington, L. Wallentin (2011)
Apixaban with antiplatelet therapy after acute coronary syndrome.The New England journal of medicine, 365 8
P. Steg, K. Huber, F. Andreotti, H. Arnesen, D. Atar, L. Badimón, J. Bassand, R. Caterina, J. Eikelboom, D. Gulba, M. Hamon, G. Helft, K. Fox, S. Kristensen, S. Rao, F. Verheugt, P. Widimsky, U. Zeymer, J. Collet (2011)
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.European heart journal, 32 15
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
J. Cairns, S. Connolly, S. McMurtry, M. Stephenson, M. Talajic (2011)
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.The Canadian journal of cardiology, 27 1
F. Andreotti, L. Testa, G. Biondi-Zoccai, F. Crea (2006)
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.European heart journal, 27 5
P. Tricoci, Zhen Huang, C. Held, D. Moliterno, P. Armstrong, F. Werf, H. White, P. Aylward, L. Wallentin, E. Chen, Y. Lokhnygina, J. Pei, S. Leonardi, Tyrus Rorick, A. Kilian, L. Jennings, G. Ambrosio, C. Bode, Á. Cequier, J. Cornel, R. Diaz, A. Erkan, K. Huber, M. Hudson, Lixin Jiang, J. Jukema, B. Lewis, A. Lincoff, G. Montalescot, J. Nicolau, H. Ogawa, M. Pfisterer, J. Prieto, W. Rużyłło, P. Sinnaeve, R. Storey, M. Valgimigli, D. Whellan, P. Widimsky, J. Strony, R. Harrington, K. Mahaffey (2012)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.The New England journal of medicine, 366 1
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 12
M. Tangelder, L. Frison, D. Weaver, R. Wilcox, A. Bylock, H. Emanuelsson, P. Held, J. Oldgren (2008)
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.American heart journal, 155 2
J. Eikelboom, S. Mehta, Sonia Anand, C. Xie, K. Fox, S. Yusuf (2006)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 114
J. Alexander, R. Lopes, S. James, R. Kilaru, Yaohua He, Puneet Mohan, Deepak Bhatt, S. Goodman, F. Verheugt, M. Flather, K. Huber, Danny Liaw, S. Husted, J. López-Sendón, R. Caterina, P. Janský, H. Darius, D. Vinereanu, J. Cornel, F. Cools, D. Atar, J. Leiva-Pons, M. Keltai, H. Ogawa, P. Pais, A. Parkhomenko, W. Rużyłło, R. Diaz, H. White, M. Ruda, M. Geraldes, J. Lawrence, R. Harrington, L. Wallentin (2011)
APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators*The New England Journal of Medicine, 8
R. Friedman (2011)
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.Orthopedics, 34 10
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
J. Alexander, R. Becker, Deepak Bhatt, F. Cools, F. Crea, M. Dellborg, K. Fox, S. Goodman, R. Harrington, K. Huber, S. Husted, B. Lewis, J. López-Sendón, Puneet Mohan, G. Montalescot, M. Ruda, W. Rużyłło, F. Verheugt, L. Wallentin (2009)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) TrialCirculation, 119
J. Oldgren, A. Budaj, C. Granger, Y. Khder, Juliet Roberts, A. Siegbahn, J. Tijssen, F. Werf, L. Wallentin (2011)
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.European heart journal, 32 22
J. Smolen, M. Schoels, Norihiro Nishimoto, F. Breedveld, G. Burmester, M. Dougados, P. Emery, G. Ferraccioli, C. Gabay, A. Gibofsky, J. Gómez-Reino, Graeme Jones, T. Kvien, M. Murakami, N. Betteridge, Clifton Bingham, V. Bykerk, Ernest Choy, B. Combe, Maurizio Cutolo, Winfried Graninger, Angel Lanas, Emilio Martín-Mola, C. Montecucco, Mikkel Ostergaard, K. Pavelka, A. Rubbert-Roth, Naveed Sattar, M. Scholte-Voshaar, Yoshiya Tanaka, M. Trauner, Gabriele Valentini, K. Winthrop, Maarten Wit, D. Heijde (2012)
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsAnnals of the Rheumatic Diseases, 72
K. Uchino, Adrian Hernández (2012)
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.Archives of internal medicine, 172 5
J. Mega, E. Braunwald, Satishkumar Mohanavelu, P. Burton, R. Poulter, F. Misselwitz, V. Hricák, E. Barnathan, P. Bordes, A. Witkowski, V. Markov, L. Oppenheimer, C. Gibson (2009)
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialThe Lancet, 374
D. Aradi, A. Komócsi, A. Vorobcsuk, O. Rideg, M. Tőkés-Füzesi, T. Magyarlaki, I. Horváth, V. Serebruany (2010)
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.American heart journal, 160 3
RS Wright, JL Anderson, CD Adams (2011)
2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons., 57
REVIEW ARTICLE Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an Acute Coronary Syndrome Systematic Review and Meta-analysis of Randomized Controlled Trials Andra´s Komo´csi, MD, PhD; Andra´s Vorobcsuk, MD, PhD; Da´niel Kehl, MS; Da´niel Aradi, MD, PhD Background: Despite receipt of dual antiplatelet therapy, ized placebo-controlled clinical trials that met the study patients after an acute coronary syndrome (ACS) re- criteria, involving 31 286 patients. Based on the pooled main at significant risk for thrombotic events. The role results, the use of new-generation oral anticoagulant of orally activated Xa antagonist (anti-Xa) and direct agents in patients receiving antiplatelet therapy after an thrombin inhibitors is debated in this setting. Our study ACS was associated with a dramatic increase in major objective was to evaluate the efficacy and safety of new- bleeding events (odds ratio, 3.03; 95% CI, 2.20-4.16; generation oral anticoagulant agents compared with pla- P .001). Significant but moderate reductions in the risk cebo in patients receiving antiplatelet therapy after an ACS. for stent thrombosis or composite ischemic events were observed, without a significant effect on overall mortal- Methods: Electronic databases were searched to iden- ity. For the net clinical benefit, treatment with new- tify
JAMA Internal Medicine – American Medical Association
Published: Nov 12, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.